Details of the Drug

General Information of Drug (ID: DMJDVCW)

Drug Name
HL-085
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Phase 1/2 [1]
Cross-matching ID
TTD ID
DJ8TN2

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
ERK activator kinase (MEK) TTZCRP3 NOUNIPROTAC Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03973151) Study of HL-085 in NRAS Mutant Advanced Melanoma. U.S. National Institutes of Health.
2 Current Development Status of MEK Inhibitors. Molecules. 2017 Sep 26;22(10):1551.
3 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
4 Clinical pipeline report, company report or official report of Roche.
5 Clinical pipeline report, company report or official report of Genentech (2011).
6 Clinical pipeline report, company report or official report of Boehringer Ingelheim.
7 MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906.